Skip to main
MLYS

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc. has garnered positive feedback based on its lead product candidate, lorundrostat, which demonstrates a significant placebo-adjusted blood pressure benefit exceeding 10 mmHg, making it a promising option for patients with uncontrolled and resistant hypertension. The company has established a differentiated profile for lorundrostat, supported by robust data from the Advance-HTN trial and anticipated feedback from the FDA, potentially positioning the candidate favorably within the biopharmaceutical market. Furthermore, the increase in the estimated percentage of patients seeking novel treatments from 10% to 12% amongst diagnosed uncontrolled hypertension patients indicates a growing unmet need that could drive future demand for lorundrostat.

Bears say

The negative outlook on Mineralys Therapeutics's stock is primarily driven by concerns regarding the company's ability to achieve projected peak commercial revenue for its product candidate, lorundrostat, which could be hindered by factors such as market size, penetration rates, and pricing strategies. Additionally, potential challenges in securing necessary capital resources to fund operations pose a significant risk, further complicating the company’s developmental and commercialization efforts. Furthermore, there are clinical considerations related to the drug's safety profile, specifically the management of hyperkalemia, which could impact patient uptake and acceptance in the market.

MLYS has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 6 analysts, MLYS has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.